114873-10-8

Basic information

• Product Name: BOC-D-2-Fluorophe
• Synonyms: RARECHEM BK PT 0023;(R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-FLUORO-PHENYL)-PROPIONIC ACID;(R)-N-BOC-2-FLUOROPHENYLALANINE;tert-Butoxycarbonyl-D-2-fluorophenylalanine;N-ALPHA-TERT-BUTYLOXYCARBONYL-D-2-FLUOROPHENYLALANINE;N-ALPHA-T-BUTOXYCARBONYL-D-(2-FLUOROPHENYL)ALANINE;N-TERT-BUTOXYCARBONYL-2-FLUOROPHENYL-D-ALANINE;D-2-FLUOROPHENYLALANINE, BOC PROTECTED
• CAS NO: 114873-10-8
• Molecular Formula: C14H18FNO4
• Molecular Weight: 283.3
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;chiral;Amino Acid Derivatives;Peptide;a-amino
• Mol File: 114873-10-8.mol

Chemical Properties

• Melting Point: 94-98 °C
• Boiling Point: 427.3 °C at 760 mmHg
• Flash Point: 212.2 °C
• Appearance: /
• Density: 1.1918 (estimate)
• Vapor Pressure: 4.61E-08mmHg at 25°C
• Storage Temp.: Keep Cold
• CAS DataBase Reference: BOC-D-2-Fluorophe(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-2-Fluorophe(114873-10-8)
• EPA Substance Registry System: BOC-D-2-Fluorophe(114873-10-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 114873-10-8(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

InChI:InChI=1/C14H18FNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-6-4-5-7-10(9)15/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m1/s1

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 19883-78-4 (S)-2-fluorophenylalanine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2629-55-2 2-fluoro-DL-phenylalanine 

Downstream Products

• 125218-22-6 (S)-2-[(S)-2-(2-{2-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-(2-fluoro-phenyl)-propionylamino]-4-methyl-pentanoic acid; hydrochloride 
• 174611-08-6 1S-1-(3,5-dibenzyloxycarbonylphenylaminocarbonyl)-2-(2-fluorophenyl)ethylamine 
• 142995-49-1 (2S,4R)-2-[(S)-1-(Benzyl-methyl-carbamoyl)-2-(2-fluoro-phenyl)-ethylcarbamoyl]-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 960207-27-6 C₂₇H₃₃N₃O₄ClF 

Relevant articles and documents

METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS

Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides

Processes and intermediates for preparing compounds of Formula (I).

Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

PCT No. PCT/IB95/00442 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed Jun. 6, 1995 PCT Pub. No. WO96/39384 PCT Pub. Date Dec. 12, 1996Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

EPOXYSUCCINIC ACID DERIVATIVES

A compound of the general formula: STR1 wherein R 1 represents a carboxyl group which may optionally be esterified or amidated; R 2 represents a cyclic group which may optionally be substituted or a polar group; n is an integer of 0 to 6; R 3 represents hydrogen or a hydrocarbon residue which may optionally be substituted; R 4 represents (1) a hydrocarbon residue which is substituted by an optionally protected amino group or (2) an alkenyl group; or R 3 and R 4 may be combined with the adjacent nitrogen atom to form a heterocyclic group containing at least two hetero atoms, or a salt thereof.The compound or a salt thereof of the present invention inhibits thiol proteases such as cathepsin L and B and serves well as a prophylactic/therapeutic agent for bone diseases such as osteoporosis.

Studies of Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N2--L-prolyl>-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds

As an extension of our studies on discovering a novel substance P (SP) antagonist, we modified the previously reported dipeptide, N2-2-(1H-indol-3-ylcarbonyl)-L-lysyl>-N-methyl-N-(phenylmethyl)-L-phenylalaninamide (2b).The lysine part in 2b was first optimized to a (2S,4R)-hydroxyproline derivative (3h), which is 2-fold more potent than 2b in SP binding assay using guinea pig lung membranes.Next we modified the 1H-indol-3-ylcarbonyl part in 3h.Introduction of a methyl group at the indole nitrogen enhanced the oral activity, while retaining the binding activity.Finally, we modified the phenylalanine part to culminate in the most potent compound 7k (FK888), which is a potent SP antagonist with NK1 selectivity as well as oral activity.